Skip to main content

Table 3 Distribution of study patients according to drug treatment

From: Epidemiology and long-term prognosis of atrial fibrillation in rural African patients

Drug Value
Antiarrhythmics
 Amiodarone, n (%) 31 (30.69)
 Betablockers, n (%) 17 (16.83)
 Digoxin, n (%) 40 (39.60)
 Calcium channel blockers, n (%) 02 (1.98)
 Amiodarone + digoxin, n (%) 11 (10.89)
Antithrombotics
 Enoxaparin, n (%) 25 (24.75)
 Vitamin K antagonist*, n (%) 4 (5.26)
 Antiplatelet agents, n (%) 84 (83.17)
ACEI/ARB, n (%) 94 (93.07)
Spironolactone, n (%) 63 (62.38)
Thiazides, n (%) 9 (8.91)
Loop diuretics, n (%) 86 (85.15)
Nitrates, n (%) 55 (54.46)
Statins, n (%) 6 (5.94)
  1. Loop diuretics and nitrates were used during the acute phase of congestive heart failure
  2. ACEI/ARB angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
  3. *Four over 76 patients at high risk of stroke received VKA